TranScrip Partners Announce Hong Kong Expansion

HONG KONG--()--TranScrip Partners, Reading UK, the specialist contract organisation today announced the opening of its Hong Kong office, TranScrip Partners Hong Kong Ltd. The new branch of TranScrip Partners will be led by James Thorburn, who has over 25 years' experience in clinical research and development involving drugs and medical devices, as well as a successful record of establishing contract research organisations both in the UK and his native Hong Kong. As part of his extensive experience in Hong Kong, James helped to establish the Clinical Trials Centre of the Faculty of Medicine, The University of Hong Kong, and currently serves as Hong Kong's Regional Director for PACRA (Pan Asian Clinical Research Association). In his new role, James will be supporting TranScrip's continuing interests in the APAC region, including China and India and will be working closely with TranScrip Partners Australia who are all already running projects in the APAC region.

The UK headquartered TranScrip Partners have recently established their office in the US. Further expansion into the APAC region is an important milestone in establishing TranScrip Partners global presence. It follows the opening of offices in Australia in September 2012 and is underpinned by the continuing increase of contracts into this region. "Establishing TranScrip's office in Hong Kong is the next step in our global strategy for growth and will consolidate our presence in Asia-Pacific, a region which we see as being highly significant with regard to pharmaceutical drug development and sales", said TranScrip's Managing Partner, Dr. Flic Gabbay.

TranScrip Partners supports biopharmaceutical product development and life-cycle management across a client base of over 80 companies in Europe, US, India, Australia, Singapore and China. TranScrip Partners challenges the traditional CRO model by offering to clients both top-level therapeutic expertise in overcoming the hurdles encountered from translational medicine to successful registration and market access and highly qualified CRO staff to support the projects. Services offered by TranScrip Partners include development and market positioning strategies for early molecules as well as tailored support in drug development, medical affairs, pharmacovigilance, regulatory and medical writing during pre and post-approval.


TranScrip Partners is a rapidly growing cutting-edge contract organisation that supports biopharmaceutical product development and life cycle management. TranScrip Partners are strategic thinkers that do, and doers who think strategically.

Working for more than 80 companies across four continents, TranScrip challenges the traditional CRO model by championing medicinal products and overcoming the hurdles encountered from translational medicine to successful registration and market access.

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.